MedTrace Logo

Efficacy and Safety of Gemcabene in Hypercholesterolemic Patients on Stable Statin Therapy

NCT02571257 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 66

Last updated 2020-04-09

No results posted yet for this study

Summary

The purpose of this study is to evaluate the effect of gemcabene on LDL-C and other lipid parameters in hypercholesterolemic patients on a stable dose of a statin.

Conditions

Interventions

DRUG

Gemcabene

1-300 mg tablet, QD, 56 days

DRUG

Gemcabene

3-300 mg tablets, QD, 56 days

DRUG

Placebo

Sponsors & Collaborators

  • NeuroBo Pharmaceuticals Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2000-08-31
Primary Completion
2002-04-30
Completion
2002-04-30

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02571257 on ClinicalTrials.gov